With Ron van Eijsden heading the Sales and Business Development team, Batavia expands its Management Team and reinforces its sales activities to support the ambitious expansion plans.
In 2021, Batavia successfully doubled its viral vector process development capacities in Woburn, MA, USA. This year, Batavia will double its infrastructure in Leiden, the Netherlands, to support the growing demand for process development and analytical capabilities in pursuit of viral vaccines and viral vector-based products. As part of its ambition, Batavia also started preparations to build a clinical and commercial manufacturing facility in Leiden, to support its clients. With these expansions, Batavia will offer end-to-end development and manufacturing support to its customers thus living up to its vision in helping to reduce human suffering from infectious diseases and cancer.
Ron van Eijsden commented: “I am excited to be part of the Center of Excellence CDMO Batavia and working to improve the affordability and availability of innovative and life-saving biopharmaceuticals. We work for some of the most exciting biopharma companies, academia, charity organizations and governmental organizations at the forefront of biopharmaceutical development. In my role as head of Business Development I can seamlessly combine my passion for networking and business development whilst making an impact on Global Health and bringing medicines to patients faster. I like that, at Batavia, it is not only about executing what our customers ask for, but about being a thought partner in designing the most optimal development roadmap”.
Ron has a PhD in molecular biology and an extensive career in business development within the red biotech industry. Prior to joining Batavia, Ron has worked in a variety of senior roles in various biopharmaceutical and biotech companies, including DCPrime, Pepscope, HAL Allergy, Catalyst Clinical Research, Linical Accelovance and Medelis Europe.